The Effect of Somatostatin, Ulinastatin and Salvia miltiorrhiza on Severe Acute Pancreatitis Treatment
The Effect of Somatostatin, Ulinastatin and Salvia miltiorrhiza on Severe Acute Pancreatitis Treatment
复制标题
生长抑素、乌司他丁、丹参治疗重症急性胰腺炎的疗效观察
DOI：
10.1097/maj.0b013e31827aa2bc
复制
发表时间：
2013-11-01
影响因子：
3.1
通讯作者：
Xiao, Xianzhong
中科院分区：
文献类型：
--
作者：
Wang, Guiliang;Wen, Jianbo;Xiao, Xianzhong
背景：本研究的目的是评价生长抑素、乌司他丁和丹参治疗重症急性胰腺炎的疗效。方法：将重症急性胰腺炎患者306例随机分为基础治疗组、生长抑素组、生长抑素+乌司他汀组、生长抑素+丹参组、生长抑素+乌司他汀+丹参组。腹痛/腹胀消退的时间，恢复到正常的心脏和呼吸频率，淀粉酶和血糖水平，急性生理和慢性健康评估II评分，肿瘤坏死因子- agr水平；分析并记录5个亚组白细胞介素(IL)-6、IL-10的变化。结果：肿瘤坏死因子-&agr；治疗后第4、7天的IL-6水平和第7天的急性生理和慢性健康评估II评分显示，生长抑素、生长抑素+乌司他汀、生长抑素+丹参和生长抑素+乌司他汀+ S丹参亚组与基础治疗亚组相比显著降低。与基础治疗组相比，生长抑素+乌司他汀、生长抑素+丹参、生长抑素+乌司他汀+丹参亚组第4、7天IL-10水平均显著提高。与基础治疗组相比，生长抑素、生长抑素+乌司他汀、生长抑素+丹参、生长抑素+乌司他汀+ S丹参亚组胰腺脓毒症、多脏器功能障碍综合征及死亡率均较低。结论：生长抑素治疗急性胰腺炎有效，乌司他丁与丹参疗效均有提高。
Background:The aim of this study was to evaluate the efficacy of somatostatin, ulinastatin and Salvia miltiorrhiza for treatment of severe acute pancreatitis. Methods:Three hundred six patients with severe acute pancreatitis were divided randomly into 5 groups: basic treatment, somatostatin, somatostatin + ulinastatin, somatostatin + S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza. Amount of time for resolution of abdominal pain/distention, recovery to normal heart and respiratory rates, amylase and blood glucose levels, Acute Physiology and Chronic Health Evaluation II scores, and levels of tumor necrosis factor-&agr;, interleukin (IL)-6, and IL-10 were analyzed and recorded for all 5 subgroups. Results:Tumor necrosis factor-&agr; and IL-6 levels on the fourth and seventh days, and Acute Physiology and Chronic Health Evaluation II scores on the seventh day after treatment showed significant decrease in the somatostatin, somatostatin + ulinastatin, somatostatin + S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza subgroups compared with the basic treatment subgroup. IL-10 levels on the fourth and seventh days were significantly improved in the somatostatin + ulinastatin, somatostatin + S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza subgroups compared with the basic treatment subgroup. The incidences of pancreatic sepsis, multiple organ dysfunction syndrome and mortality were lower in the somatostatin, somatostatin + ulinastatin, somatostatin + S miltiorrhiza and somatostatin + ulinastatin + S miltiorrhiza subgroups compared with the basic treatment subgroup. Conclusions:Somatostatin is effective for the treatment of acute pancreatitis and both ulinastatin and S miltiorrhiza demonstrate improvement in therapeutic benefits.